The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

被引：0
|
作者：
Nenad Sarapa
Margaret R. Britto
Michelle B. Mainka
Kourosh Parivar
机构：
[1] Clinical PK/PD,Pfizer Global Research & Development
[2] Clinical Pharmacology,Quintiles Inc.
[3] Statistics and Programming,Pfizer Global Research & Development
来源：
European Journal of Clinical Pharmacology | 2005年 / 61卷
关键词：
Valdecoxib; Pharmacokinetics; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 256
页数：9
相关论文
共 50 条
  • [31] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04): : 446 - 452
  • [32] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [33] The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: Results of a randomized controlled trial
    Leese, PT
    Recker, DP
    Kent, JD
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05): : 504 - 513
  • [34] Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)
    Kovacs, Steven J.
    Ke, June
    Praestgaard, Jens
    Barve, Avantika
    Zhang, Jie
    Maietta, Robert
    Sunkara, Gangadhar
    Stein, Daniel S.
    GASTROENTEROLOGY, 2013, 144 (05) : S977 - S977
  • [35] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF TASOCITINIB (CP-690,550)
    Lawendy, N.
    Chan, G.
    Wang, R.
    Lamba, M.
    Krishnaswami, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S93 - S94
  • [36] Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen
    Yan, Jing-He
    Taylor, Amanda
    Clough, Timothy
    Burmeister-Getz, Elise
    Pazdirkova, Marketa
    Russo, Cesare
    CIRCULATION, 2024, 150
  • [37] Valdecoxib - A COX-2 inhibitor for treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea
    Goldman, M
    Schutzer, S
    FORMULARY, 2002, 37 (02) : 68 - +
  • [38] No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
    Wåhlander, K
    Eriksson-Lepkowska, M
    Frison, L
    Fager, G
    Eriksson, UG
    CLINICAL PHARMACOKINETICS, 2003, 42 (08) : 755 - 764
  • [39] Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.
    Giri, Nagdeep
    Plotka, Anna
    Liang, Yali
    Boutros, Tanya
    Ni, Grace
    Masters, Joanna
    DeMicco, Michael
    Pardo, Patricia
    Bello, Carlo
    O'Connell, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] PHARMACOKINETICS (PK) OF THE PAN-HER INHIBITOR DACOMITINIB (D) IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    O'Connell, J.
    Plotka, A.
    Liang, Y.
    Boutros, T.
    Ni, G.
    Masters, J.
    DeMicco, M.
    Pardo, P.
    Bello, C.
    Giri, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 83 - 83
12345